192 citations
,
January 2015 in “Journal of the American Academy of Dermatology” This review discusses skin-related toxicities associated with targeted cancer therapies and emphasizes the need for dermatologists to understand and manage these adverse effects, but reports no new experimental results.
149 citations
,
January 2015 in “Journal of the American Academy of Dermatology” This review discusses skin-related adverse effects from targeted cancer therapies in dermatology but does not provide new clinical results, emphasizing the essential role of dermatologists in managing these toxicities.
31 citations
,
March 2014 in “Journal of the European Academy of Dermatology and Venereology” In this study, multiple cutaneous adverse effects were observed in patients with metastatic malignant melanoma receiving BRAF inhibitors, but most were well managed with appropriate treatment.
10 citations
,
September 2016 in “Journal of cutaneous medicine and surgery” In this prospective study, dabrafenib and trametinib were associated with various skin side effects, including papillomas, hyperkeratosis, and acneiform eruptions in patients with metastatic melanoma.
January 2026 in “Clinical & Translational Oncology” This expert consensus statement highlights that while targeted cancer therapies significantly improve patient survival, they often result in various skin toxicities, underscoring the need for early diagnosis, management, and multidisciplinary care to maintain patients' quality of life and ensure treatment continuity.